ZETTA GENOMICS LIMITED
Zetta Genomics Limited, a research company based in Norwich, entered administration under Schedule B1 of the Insolvency Act 1986 on 19 February 2026. Joint administrators from FRP Advisory Trading, including Hayley Watson, were appointed by the directors or a floating-charge holder. This transition occurred despite the company maintaining a compliant filing record, including full accounts submitted on 16 July 2025.
What the data was telling us
Readings from The Gazette and Companies House, in the firm's final two years.
Lessons behind the liquidation
The company registered three charges on 26 July 2024 with HSBC Innovation Banking, which are recorded as fully satisfied. While clearing secured liabilities improves the balance sheet position, the subsequent administration on 19 February 2026 shows that a clean debt registry does not necessarily protect a company from cash flow pressures.
The company maintained four active directors at the time of insolvency, with nine appointments since 2018 and an average tenure of 3.1 years. Crucially, there were zero resignations in the final 12 months, indicating a stable leadership team leading up to the administration. This demonstrates that a cohesive board and low leadership turnover cannot always insulate a business from broader financial headwinds in the research sector.
Zetta Genomics Limited filed full accounts on 16 July 2025 and maintained an active confirmation statement. The transition to administration on 19 February 2026, following the accounts filed on 16 July 2025, illustrates how quickly financial health can deteriorate. Public filings remain a lagging indicator of a firm's real time cash position.
This case resembles a broader pattern of research enterprises that maintain high standards of regulatory compliance and debt resolution but ultimately face sudden liquidity exhaustion before achieving self sustaining commercial scale.
Every charge, every filing, every appointment, in one dossier.
Director histories across related entities, the full debenture instrument, creditor estimates, and the practitioner's record on comparable cases for ZETTA GENOMICS LIMITED.